Autres langues Capricor Therapeutics, Inc.

Actions

CAPR

US14070B3096

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:07:21 05/10/2026			Varia. 5j.	Varia. 1 janv.
8,160 ^USD	-8,83%		-5,91%	-71,60%

18:35	Capricor Therapeutics présente des données positives de l’étude d’extension en ouvert HOPE-3 sur le déramiocel pour la fonction des membres supérieurs dans la dystrophie musculaire de Duchenne	CI
30/09	Principales hausses avant l’ouverture	MT

Autres langues

18:35	Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data On Deramiocel For Upper Limb Function In Duchenne Muscular Dystrophy
15:01	Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
30/09	Top Premarket Gainers
22/09	SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
17/09	CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Capricor Therapeutics, Inc. (CAPR) Investors to Inquire About a Securities Fraud Class Action by September 28, 2026
17/09	Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
14/09	Capricor Therapeutics Shares Rise After Upgrade From B. Riley
11/09	SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
09/09	CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Capricor Therapeutics, Inc. (CAPR) Investors to Inquire About a Securities Fraud Class Action by September 28, 2026
09/09	LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
08/09	CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 28, 2026 Deadline - RGRD Law
03/09	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
02/09	Capricor Therapeutics, Inc. (CAPR) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
01/09	Capricor Therapeutics Shares Rise After Piper Sandler Upgrade
01/09	CAPRICOR THERAPEUTICS, INC. (CAPR) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Class Action by September 28, 2026
31/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
28/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
28/08	Capricor Therapeutics, Inc. (CAPR) Securities Fraud: Contact Berger Montague To Discuss Your Rights
27/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
24/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
24/08	Capricor Therapeutics Shares Rise as FDA Extends Deramiocel Review
24/08	Capricor Therapeutics Says FDA Target Action Date for Deramiocel Extended by Three Months
24/08	Capricor's Duchenne drug gets three-month FDA extension after new data submission
24/08	Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
24/08	Capricor Therapeutics Announces Extension Of PDUFA Target Action Date As FDA Continues Review Of Deramiocel BLA